The discussion about the relocation of the EMA has kick-started and EU leaders are expected to make a final decision in November.
More than 20 member states have already expressed their interest in hosting the EU drug agency. Analysts say the talks have inevitably been politicised.
However, the pharmaceutical industry and consumer groups are urging EU leaders to focus on business continuity and avoid potential risks for patients.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has said that the main priority is to put an end to the uncertainty over the location of the EMA, as well as to ensure transitional arrangements are in place for issues that can impact on patient safety and health.